No Data
No Data
Sichuan Kelun-Biotech Subscribes to 250 Million Yuan Structured Deposits of Bank of Chengdu
GTJA initiates coverage of Corinth Bio(B) with a "shareholding" rating and a target price of HKD 198.43.
GTJA expects that the revenue of Coronavac Biotech-B (06990) will be 1.181/1.574/2.361 billion yuan from 2024 to 2026.
Kolon Life Science-B (6990.HK): Showing initial sharpness, the leading Chinese ADC competes for the global market.
Report summary: The company is the leader in domestic ADC drugs, with core varieties entering into harvest period one after another. TROP2 ADC SKB264 has the best global potential among similar products, backed by Merck with huge market potential. This is the first coverage, giving a
Rate cut bullish boosts Hong Kong stocks! Technology index leads the three major indices, with education and internet plus-related stocks performing well.
Besides the rate cut, what other good news is there in the Hong Kong stock market? Why did CITIC Securities rise? Why did Jiumaojiu drop today?
CMB International: bullish on the rebound of Mainland China's pharmaceutical industry, with continued bullish policy implementation.
Zhaojin International continues to be bullish on Shenzhen Mindray Bio-Medical Electronics, United Imaging Medical, Innovent Bio (01801), Beigene (06160), Genscript Biotech (02273), Kelun Pharma (06990), and Anpac Bio-Medical Science (02367).
Ping An Securities: Nuclear medicine has multiple clinical advantages, and high barriers to entry have created an oligopolistic monopoly pattern.
It is expected that from 2023 to 2030, China's nuclear medicine market will grow from 5 billion yuan to 26 billion yuan at a CAGR of 26.6%.
No Data